Stock listing

BCBA:ABBV AbbVie Inc. Acciones

Argentine listing (BCBA) of AbbVie Inc. · home listing NYSE:ABBV

Follow AbbVie Inc. into a list and get an email when it puts out news.

Home listing price · NYSE:ABBV

$286.20 USD +0.19 (+0.1%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NYSE:ABBV

Past year +24.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$284.85 – $290.23 USDNov 20, 2026
Volume
8.76M sharesNov 20, 2026
Market cap
$505.9B USDAt the close on Nov 20, 2026 · price × 1.77B shares outstanding
52-week range
$190.75 – $302.93 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$1.33B USDMedian day 4.43M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
AbbVie Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NYSE:ABBV · Home$286.20 USD+0.19 (+0.1%)8,755,117$286.83$290.23$284.85$286.01Close on Nov 20, 2026
TSX:ABBV$39.79 CAD+0.63 (+1.6%)15,795$39.79$40.14$39.68$39.16Close on Nov 20, 2026
Xetra:4AB€262.50 EUR+5.90 (+2.3%)211€260.90€263.70€258.70€256.60Close on Nov 20, 2026
Cboe Canada:ABBV$39.91 CAD+0.45 (+1.1%)100$39.91$39.91$39.91$39.46Close on Nov 20, 2026
B3:ABBV34105.62 BRL+0.15 (+0.1%)1,953103.90105.62103.50105.47Close on Nov 19, 2026
BMV:ABBV$5,537.00 MXN+134.00 (+2.5%)75$5,537.00$5,537.00$5,537.00$5,403.00Close on Nov 20, 2026
Frankfurt:4AB€262.80 EUR+2.70 (+1.0%)—€259.20€262.80€258.60€260.10Close on Nov 20, 2026
Stuttgart:4AB€260.80 EUR+2.60 (+1.0%)21€258.00€263.70€258.00€258.20Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NYSE:ABBV · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$286.20+0.19+0.1%$286.83$290.23$284.858,755,117
$286.01-6.81-2.3%$290.00$292.55$284.914,769,805
$292.82-1.73-0.6%$291.50$294.06$291.003,925,606
$294.55-0.48-0.2%$299.98$301.18$293.974,707,805
$295.03+0.58+0.2%$296.58$297.25$293.563,259,640
$294.45-0.53-0.2%$299.30$300.42$294.094,760,280
$294.98+1.09+0.4%$291.36$295.46$289.733,177,657
$293.89+0.59+0.2%$292.50$294.50$291.043,471,430
$293.30+1.99+0.7%$293.84$294.57$289.625,822,420
$291.31+3.07+1.1%$282.27$291.73$281.075,017,683
$288.24-6.59-2.2%$298.74$302.93$287.797,881,739
$294.83+8.83+3.1%$293.95$295.40$283.328,408,135
$286.00-2.84-1.0%$288.69$291.32$284.715,348,839
$288.84-6.05-2.1%$290.38$294.86$286.148,849,994
$294.89+4.10+1.4%$292.00$298.74$291.016,896,546
$290.79+4.80+1.7%$291.00$292.58$288.044,302,025
$285.99-0.40-0.1%$282.93$288.80$281.233,110,629
$286.39-0.35-0.1%$283.88$287.32$283.163,267,429
$286.74+1.10+0.4%$287.05$289.59$285.184,322,608
$285.64+0.45+0.2%$284.58$286.77$282.304,597,666
$285.19+0.39+0.1%$284.57$285.74$278.016,172,149
$284.80-4.28-1.5%$287.63$289.00$282.164,391,916
$289.08+6.40+2.3%$286.90$290.98$285.005,173,961
$282.68-2.74-1.0%$284.23$287.93$282.593,986,797
$285.42+2.02+0.7%$283.61$286.64$282.965,776,793
$283.40-0.080.0%$288.28$291.40$282.817,621,730
$283.48+9.12+3.3%$277.00$285.40$275.975,633,169
$274.36-6.76-2.4%$283.29$283.43$273.706,408,500
$281.12+4.65+1.7%$277.65$281.30$276.015,593,700
$276.47+4.05+1.5%$271.53$277.60$270.384,297,946
$272.42+1.06+0.4%$270.98$272.52$265.715,494,940
$271.36+4.67+1.8%$268.40$274.94$266.896,079,078
$266.69+0.93+0.3%$267.74$268.86$260.624,501,087
$265.76+2.94+1.1%$261.27$267.34$260.297,544,505
$262.82+2.89+1.1%$259.74$264.06$257.875,863,068
$259.93-1.66-0.6%$260.51$262.32$259.003,892,076
$261.59-1.70-0.6%$264.60$265.36$261.594,389,160
$263.29-2.99-1.1%$265.45$268.93$261.524,004,368
$266.28+1.94+0.7%$264.33$267.74$263.384,429,512
$264.34-0.78-0.3%$265.49$266.00$262.592,541,718
$265.12+0.040.0%$265.37$267.41$263.093,458,166
$265.08-0.130.0%$266.00$269.39$263.593,469,242
$265.21+0.73+0.3%$263.10$266.82$262.152,766,286
$264.48+0.52+0.2%$263.07$266.60$261.233,438,150
$263.96-0.060.0%$263.29$266.34$262.448,176,607
$264.02+1.51+0.6%$262.61$264.62$260.883,509,941
$262.51-0.53-0.2%$261.99$264.00$260.983,118,268
$263.04+1.27+0.5%$260.00$264.81$257.805,120,219
$261.77+4.65+1.8%$261.67$264.65$260.104,512,420
$257.12+2.12+0.8%$253.92$259.61$253.924,308,856
$255.00+4.09+1.6%$251.23$255.31$249.744,397,653
$250.91+2.13+0.9%$247.73$251.18$246.773,866,951
$248.78-7.68-3.0%$251.84$254.62$248.415,572,102
$256.46-3.75-1.4%$257.96$258.91$255.584,729,800
$260.21-1.51-0.6%$264.00$264.25$257.142,878,739
$261.72+1.73+0.7%$262.70$262.97$257.704,225,524
$259.99+3.57+1.4%$260.99$262.27$257.793,866,739
$256.42+0.94+0.4%$254.17$258.24$252.334,315,487
$255.48-2.67-1.0%$258.67$259.00$255.083,224,862
$258.15-4.75-1.8%$260.81$262.50$257.254,764,797
$262.90-2.89-1.1%$264.60$265.00$260.313,308,871
$265.79+1.27+0.5%$264.50$266.91$263.033,671,623
$264.52-0.44-0.2%$263.99$266.04$262.073,883,803
$264.96+3.13+1.2%$260.70$266.84$260.105,157,192
$261.83-4.14-1.6%$265.69$265.93$260.485,228,907
Ticker
BCBA:ABBV
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
BCBA
Currency
ARS

What changed lately

Latest news

ABBV 3Q26 Press Release Final

Oct 30, 2026

Closed $294.89 (+1.4%) on Oct 30, 2026

All AbbVie Inc. news

AbbVie Inc. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
140 in the last 12 months · 191 in all · newest Nov 20, 2026 · oldest 2025
Calls
32 calls with a replay · 32 with a transcript · latest Oct 30, 2026
Decks
33 decks · latest Jun 22, 2026

Where AbbVie Inc. is listed

ListingExchangeCountryCurrency
NYSE:ABBV · Home listingNYSEUnited StatesUSD
gettex:4ABgettexGermanyEUR
BCBA:ABBV · This pageBCBAArgentinaARS
SET:ABBV19SETThailandTHB
Tradegate:4ABTradegateGermanyEUR
TSX:ABBVTSXCanadaCAD
Xetra:4ABXetraGermanyEUR
Cboe Canada:ABBVCboe CanadaCanadaCAD
B3:ABBV34B3BrazilBRL
SET:ABBV80SETThailandTHB
LS Exchange:A1J84ELS ExchangeGermanyEUR
BMV:ABBVBMVMexicoMXN
Milan:1ABBVMilanItalyEUR
BCBA:ABBVDBCBAArgentinaUSD
LSIN:0QCVLSINUnited KingdomUSD
EUROTLX:4ABBVEUROTLXItalyEUR
Frankfurt:4ABFrankfurtGermanyEUR
Lang & Schwarz:A1J84ELang & SchwarzGermanyEUR
SIX Swiss:ABBVSIX SwissSwitzerlandCHF
Stuttgart:4ABStuttgartGermanyEUR
BIVA:ABBVBIVAMexicoMXN
BCBA:ABBVCBCBAArgentinaUSD
BOATS:ABBVBOATSUnited StatesUSD
VIE:ABBVViennaAustriaEUR
Munich:4ABMunichGermanyEUR
BCS:ABBVBCSChileUSD
Dusseldorf:4ABDusseldorfGermanyEUR
BX Swiss:4ABBX SwissSwitzerlandCHF
Hamburg:4ABHamburgGermanyEUR
BSESOF:4ABBSESOFBulgariaEUR
Dusseldorf:4AB0DusseldorfGermanyEUR
Frankfurt:4AB0FrankfurtGermanyEUR
SIX Swiss:ABBV.USDSIX SwissSwitzerlandUSD
BCS:ABBVCLBCSChileCLP
Turquoise:4ABDTurquoiseUnited KingdomEUR
BCBA:ABBV.CIBCBAArgentinaARS
Hanover:4ABHanoverGermanyEUR

Valuation

P/E 48.9× against a median of 28.8×: 10th lowest of 11 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$503.8B USD
P/E
48.9×
EV/sales
7.6×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
Negative equity
Gross margin
73.7%
Operating margin
Not reported
Net margin
15.7%
Debt to equity
Negative equity
Beta vs S&P 500
0.00

Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
AbbVie Inc. · NYSE:ABBVUS$505.9BUS$503.8B48.9×7.6×n/an/a15.7%n/a0.00
Eli Lilly and Company · NYSE:LLYUS$1.27TUS$1.31T46.0×15.1×n/a31.5×31.9%1.2×0.34
Johnson & Johnson · NYSE:JNJUS$651.1BUS$678.5B40.5×6.8×n/a8.0×16.2%0.6×-0.02
Merck & Company, Inc. · NYSE:MRKUS$329.7BUS$373.8B134×5.5×n/a7.3×3.6%1.2×0.28
Novartis AG · SIX:NOVNUS$287.4BUS$304.7B20.6×n/an/a6.2×n/a0.6×n/a
AstraZeneca PLC · LSE:AZNUS$272.1BUS$298.0B24.6×4.8×14.1×5.3×17.7%0.7×n/a
Pfizer, Inc. · NYSE:PFEUS$156.2BUS$207.8B38.7×3.3×9.6×1.8×6.3%0.7×0.29
Vertex Pharmaceuticals Incorporated · NASDAQ:VRTXUS$130.6BUS$128.8B32.8×9.9×28.4×6.3×30.7%0.2×0.47
Novo Nordisk A/S Class B · OMXCOP:NOVO_BUS$129.4BUS$142.3B7.8×2.9×5.5×4.0×33.9%0.6×n/a
Bristol-Myers Squibb Company · NYSE:BMYUS$120.2BUS$151.3B13.0×3.0×n/a5.1×18.5%1.9×0.26
Sanofi SA · EURONEXT:SANUS$111.7BUS$126.9B14.6×2.3×4.7×1.4×13.9%0.3×n/a
Median of the othersUS$214.1BUS$252.9B28.8×4.8×9.6×5.8×17.7%0.6×0.29

Forecasts

16 strong buy · 7 buy · 5 hold · 1 sell · Analysts' consensus from EODHD, read Nov 22, 2026. Not 6ix's view and not investment advice.

Price target
315.88 USD · Analysts' mean
EPS, year to Dec 2026
13.98 · 29 analysts
Revenue, year to Dec 2026
67.79B · 26 analysts

Team and board

Officers

OfficerRole
Robert A. MichaelChairman of the Board and Chief Executive Officer
Brett J. HartPresident
Roxanne S. AustinPresident
Adelle InfanteCorporate Communications

Board

DirectorRole
Robert A. MichaelChairman of the Board and Chief Executive Officer
William H.L. BurnsideDirector

Events

Calls

CallWhenStatus
AbbVie (NYSE:ABBV) Q3 2026 Earnings CallFri, Oct 30, 2026 · 9:00 AM ETReplay
AbbVie (NYSE:ABBV) Q2 2026 Earnings CallFri, Jul 31, 2026 · 9:00 AM ETReplay
AbbVie (NYSE:ABBV) Q1 2026 Earnings CallWed, Apr 29, 2026 · 9:00 AM ETReplay
AbbVie (NYSE:ABBV) Q4 2025 Earnings CallWed, Feb 04, 2026 · 9:00 AM ETReplay
AbbVie (NYSE:ABBV) Q3 2025 Earnings CallFri, Oct 31, 2025 · 9:00 AM ETReplay
AbbVie (NYSE:ABBV) Q2 2025 Earnings CallThu, Jul 31, 2025 · 9:00 AM ETReplay
AbbVie (NYSE:ABBV) Q1 2025 Earnings CallFri, Apr 25, 2025 · 9:00 AM ETReplay
AbbVie (NYSE:ABBV) Q4 2024 Earnings CallFri, Jan 31, 2025 · 9:00 AM ETReplay
AbbVie (NYSE:ABBV) Q3 2024 Earnings CallWed, Oct 30, 2024 · 9:00 AM ETReplay
AbbVie (NYSE:ABBV) Q2 2024 Earnings CallThu, Jul 25, 2024 · 9:00 AM ETReplay
All 32 calls
CallWhenStatus
AbbVie (NYSE:ABBV) Q1 2024 Earnings CallFri, Apr 26, 2024 · 8:00 AM ETReplay
AbbVie (NYSE:ABBV) Q4 2023 Earnings CallFri, Feb 02, 2024 · 9:00 AM ETReplay
AbbVie (NYSE:ABBV) Q3 2023 Earnings CallFri, Oct 27, 2023 · 9:00 AM ETReplay
AbbVie (NYSE:ABBV) Q2 2023 Earnings CallThu, Jul 27, 2023 · 9:00 AM ETReplay
AbbVie (NYSE:ABBV) Q1 2023 Earnings CallThu, Apr 27, 2023 · 9:00 AM ETReplay
AbbVie (NYSE:ABBV) Q4 2022 Earnings CallThu, Feb 09, 2023 · 9:00 AM ETReplay
AbbVie (NYSE:ABBV) Q3 2022 Earnings CallFri, Oct 28, 2022 · 9:00 AM ETReplay
AbbVie (NYSE:ABBV) Q2 2022 Earnings CallFri, Jul 29, 2022 · 9:00 AM ETReplay
AbbVie (NYSE:ABBV) Q1 2022 Earnings CallFri, Apr 29, 2022 · 9:00 AM ETReplay
AbbVie (NYSE:ABBV) Q4 2021 Earnings CallWed, Feb 02, 2022 · 9:00 AM ETReplay
AbbVie (NYSE:ABBV) Q3 2021 Earnings CallFri, Oct 29, 2021 · 9:00 AM ETReplay
AbbVie (NYSE:ABBV) Q2 2021 Earnings CallFri, Jul 30, 2021 · 9:00 AM ETReplay
AbbVie (NYSE:ABBV) Q1 2021 Earnings CallFri, Apr 30, 2021 · 9:00 AM ETReplay
AbbVie (NYSE:ABBV) Q4 2020 Earnings CallWed, Feb 03, 2021 · 9:00 AM ETReplay
AbbVie (NYSE:ABBV) Q3 2020 Earnings CallFri, Oct 30, 2020 · 9:00 AM ETReplay
AbbVie (NYSE:ABBV) Q2 2020 Earnings CallFri, Jul 31, 2020 · 9:00 AM ETReplay
AbbVie (NYSE:ABBV) Q1 2020 Earnings CallFri, May 01, 2020 · 9:00 AM ETReplay
AbbVie (NYSE:ABBV) Q4 2019 Earnings CallFri, Feb 07, 2020 · 9:00 AM ETReplay
AbbVie (NYSE:ABBV) Q3 2019 Earnings CallFri, Nov 01, 2019 · 9:00 AM ETReplay
AbbVie (NYSE:ABBV) Q2 2019 Earnings CallFri, Jul 26, 2019 · 9:00 AM ETReplay
AbbVie (NYSE:ABBV) Q1 2019 Earnings CallThu, Apr 25, 2019 · 9:00 AM ETReplay
AbbVie (NYSE:ABBV) Q4 2018 Earnings CallFri, Jan 25, 2019 · 9:00 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Oct 30, 2026 · Before open+1.4%
Q2 2026Jul 31, 2026 · Before open−2.5%
Q1 2026Apr 29, 2026 · Before open+3.1%
Q4 2025Feb 4, 2026 · Before open−3.8%
Q3 2025Oct 31, 2025 · Before open−4.5%
Q2 2025Jul 31, 2025 · Before open−0.1%
Q1 2025Apr 25, 2025 · Before open+3.1%
Q4 2024Jan 31, 2025 · Before open+4.7%
Q3 2024Oct 30, 2024 · Before open+6.4%
Q2 2024Jul 25, 2024 · Before open+3.4%
All 20 quarters
QuarterResultsShare move
Q1 2024Apr 26, 2024 · Before open−4.6%
Q4 2023Feb 2, 2024 · Before open+0.6%
Q3 2023Oct 27, 2023 · Before open−4.3%
Q2 2023Jul 27, 2023 · Before open+4.9%
Q1 2023Apr 27, 2023 · Before open−8.0%
Q4 2022Feb 9, 2023 · Before open+2.8%
Q3 2022Oct 28, 2022 · Before open−3.8%
Q2 2022Jul 29, 2022 · Before open−4.2%
Q1 2022Apr 29, 2022 · Before open−6.0%
Q4 2021Feb 2, 2022 · Before open+1.2%

Open Events

Decks

DeckKindSlidesDate
Merger or Acquisition (June 2026)Merger or acquisition15 slidesJun 22, 2026
Q4 2025 Earnings PresentationEarnings4 slidesFeb 4, 2026
Q1 2025 Earnings PresentationEarnings9 slidesApr 25, 2025
Fact Sheet (2025)Fact sheet6 slides2025
Investor Presentation (2024)Investor deck21 slidesMay 2, 2024
Investor Presentation (2024)Investor deck21 slides2024
Merger or Acquisition (December 2023)Merger or acquisition14 slidesDec 6, 2023
Merger or Acquisition (November 2023)Merger or acquisition14 slidesNov 30, 2023
Q3 2023 Earnings PresentationEarnings13 slidesOct 27, 2023
Fact Sheet (August 2023)Fact sheet1 slideAugust 2023
All 33 decks
DeckKindSlidesDate
Q4 2022 Earnings PresentationEarnings4 slidesFeb 9, 2023
J.P. Morgan Healthcare Conference 2023Conference20 slidesJan 10, 2023
Investor Presentation (2022)Investor deck35 slidesJun 6, 2022
Q4 2021 Earnings PresentationEarnings4 slidesFeb 2, 2022
Fact Sheet (February 2022)Fact sheet1 slideFebruary 2022
J.P. Morgan Healthcare Conference 2022Conference21 slidesJan 11, 2022
Fact Sheet (September 2021)Fact sheet1 slideSeptember 2021
J.P. Morgan Healthcare Conference 2021Conference21 slidesJan 12, 2021
Fact Sheet (November 2020)Fact sheet1 slideNov 26, 2020
Investor Day (March 2020)Investor day122 slidesMar 10, 2020
Merger or Acquisition (June 2019)Merger or acquisition28 slidesJun 25, 2019
Jefferies Healthcare Conference 2018Conference11 slidesJun 6, 2018
J.P. Morgan Healthcare Conference 2018Conference20 slidesJan 10, 2018
Jefferies Healthcare Conference 2017Conference9 slidesJun 8, 2017
J.P. Morgan Healthcare Conference 2017Conference18 slidesJan 11, 2017
J.P. Morgan Healthcare Conference 2016Conference16 slidesJan 13, 2016
Investor Day (October 2015)Investor day33 slidesOct 30, 2015
Investor Presentation (2015)Investor deck8 slidesSep 6, 2015
Merger or Acquisition (March 2015)Merger or acquisition20 slidesMar 5, 2015
Fact Sheet (January 2015)Fact sheet6 slidesJanuary 2015
Merger or Acquisition (June 2014)Merger or acquisition40 slidesJun 25, 2014
J.P. Morgan Healthcare Conference 2013Conference17 slidesJan 8, 2013
Investor PresentationInvestor deck22 slides

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue61.2B56.3B54.3B58.1B56.2B45.8B33.3B32.8B28.2B25.6B
Cost of revenue18.2B16.9B20.4B17.4B17.4B15.4B7.44B7.72B7.04B5.83B
Gross profit43.0B39.4B33.9B40.6B38.8B30.4B25.8B25.0B21.2B19.8B
Research and development9.10B12.8B7.67B6.51B6.92B6.38B6.41B10.3B5.01B4.38B
Selling, general and administrative14.0B14.8B12.9B15.3B12.3B11.3B6.94B7.40B6.29B5.88B
Operating income15.1B9.14B12.8B18.1B17.9B11.4B13.0B6.38B9.54B9.34B
Depreciation and amortization762.0M764.0M752.0M778.0M803.0M666.0M464.0M471.0M425.0M425.0M
EBITDA15.8B9.90B13.5B18.9B18.7B12.0B13.4B6.85B9.97B9.77B
Interest expense2.89B2.81B2.22B2.23B2.42B2.45B1.78B1.35B1.15B1.05B
Income before tax6.60B3.72B6.25B13.5B13.0B3.40B8.43B5.20B7.73B7.88B
Income tax2.36B-570.0M1.38B1.63B1.44B-1.22B544.0M-490.0M2.42B1.93B
Net income4.23B4.28B4.86B11.8B11.5B4.62B7.88B5.69B5.31B5.95B
Earnings per share, basic2.372.402.736.656.482.735.303.673.313.65
Earnings per share, diluted2.362.392.726.636.452.725.283.663.303.63

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents5.23B5.52B12.8B9.20B9.75B8.45B39.9B7.29B9.30B5.10B
Short-term investments28.0M31.0M2.00M28.0M84.0M30.0M0772.0M486.0M1.32B
Receivables12.6B10.9B11.2B11.3B9.98B8.82B5.43B5.38B5.09B4.76B
Inventory4.95B4.18B4.10B3.58B3.13B3.31B1.81B1.60B1.60B1.44B
Current assets29.1B25.6B33.0B28.5B27.9B24.2B49.5B16.9B21.2B16.2B
Property, plant and equipment5.63B5.13B4.99B4.93B5.11B5.25B2.96B2.88B2.80B2.60B
Goodwill35.6B35.0B32.3B32.2B32.4B33.1B15.6B15.7B15.8B15.4B
Total assets134.0B135.2B134.7B138.8B146.5B150.6B89.1B59.4B70.8B66.1B
Accounts payable3.59B2.94B3.69B2.93B2.88B2.28B1.45B1.55B1.47B1.41B
Current liabilities43.3B38.7B37.8B29.5B35.2B28.7B15.6B17.2B16.6B9.78B
Long-term debt58.9B60.3B52.2B59.1B64.2B77.6B63.0B35.0B31.0B36.4B
Total debt67.0B66.8B59.2B63.1B76.0B85.0B67.2B5.31B6.42B402.0M
Shareholders' equity-3.27B3.33B10.4B17.3B15.4B13.1B-8.17B-8.45B5.10B4.64B
Shares outstanding1.77B1.77B1.77B1.77B1.77B1.77B1.77B1.77B1.48B1.48B

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations19.0B18.8B22.8B24.9B22.8B17.6B13.3B13.4B9.96B7.04B
Capital spending-1.21B-974.0M-777.0M-695.0M-787.0M-798.0M-552.0M-638.0M-529.0M-479.0M
Free cash flow17.8B17.8B22.1B24.2B22.0B16.8B12.8B12.8B9.43B6.56B
Cash from investing-6.64B-20.8B-2.01B-623.0M-2.34B-37.6B596.0M-1.01B-274.0M-6.07B
Cash from financing-12.7B-5.21B-17.2B-24.8B-19.0B-11.5B18.7B-14.4B-5.51B-3.93B
Dividends paid-11.7B-11.0B-10.5B-10.0B-9.26B-7.72B-6.37B-5.58B-4.11B-3.72B
Share buybacks-980.0M-1.71B-1.97B-1.49B-934.0M-978.0M-629.0M-12.0B-1.41B-6.03B
Change in cash-295.0M-7.29B3.61B-545.0M1.30B-31.5B32.6B-2.01B4.20B-3.30B

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 18, 2026Insider tradeSEC
144 · Notice of proposed saleNov 16, 2026Other filingsSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
144 · Notice of proposed saleNov 9, 2026Other filingsSEC
10-Q · Quarterly reportNov 3, 2026Quarterly reportSEC
8-K · Current reportNov 2, 2026Management or board changeSEC
8-K · Current reportOct 30, 2026ResultsSEC
3 · Initial statement of ownershipOct 23, 2026Insider tradeSEC
8-K · Current reportOct 15, 2026Management or board changeSEC
8-K · Current reportOct 5, 2026ResultsSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipOct 2, 2026Insider tradeSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
8-K · Current reportSep 3, 2026Current reportSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
8-K · Current reportAug 18, 2026Current reportSEC
144 · Notice of proposed saleAug 14, 2026Other filingsSEC
424B5 · ProspectusAug 6, 2026Offer documentSEC
8-K · Current reportAug 5, 2026Current reportSEC
FWP · Free writing prospectusAug 4, 2026Offer documentSEC
424B5 · ProspectusAug 4, 2026Offer documentSEC
10-Q · Quarterly reportAug 3, 2026Quarterly reportSEC
8-K · Current reportJul 31, 2026ResultsSEC
8-K · Current reportJul 6, 2026ResultsSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
11-K · Annual report of an employee planJun 24, 2026Annual reportSEC
8-K · Current reportJun 22, 2026Current reportSEC
SD · Specialized disclosureJun 1, 2026ESG reportSEC
144 · Notice of proposed saleMay 26, 2026Other filingsSEC
8-K · Current reportMay 12, 2026Meeting outcomeSEC
4 · Change in ownershipMay 12, 2026Insider tradeSEC
4 · Change in ownershipMay 12, 2026Insider tradeSEC
4 · Change in ownershipMay 12, 2026Insider tradeSEC
4 · Change in ownershipMay 12, 2026Insider tradeSEC
4 · Change in ownershipMay 12, 2026Insider tradeSEC
4 · Change in ownershipMay 12, 2026Insider tradeSEC
4 · Change in ownershipMay 12, 2026Insider tradeSEC
4 · Change in ownershipMay 12, 2026Insider tradeSEC
4 · Change in ownershipMay 12, 2026Insider tradeSEC
4 · Change in ownershipMay 12, 2026Insider tradeSEC
4 · Change in ownershipMay 12, 2026Insider tradeSEC
10-Q · Quarterly reportMay 8, 2026Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeApr 29, 2026Big-stake noticeSEC
8-K · Current reportApr 29, 2026ResultsSEC
8-K · Current reportApr 3, 2026ResultsSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 26, 2026Big-stake noticeSEC
ARS · Annual report to shareholdersMar 23, 2026Annual reportSEC
DEFA14A · Additional proxy materialMar 23, 2026Meeting noticeSEC
DEF 14A · Proxy statementMar 23, 2026Meeting noticeSEC
4/A · Change in ownership, amendedMar 11, 2026Insider tradeSEC
PRE 14A · Preliminary proxy statementMar 9, 2026Meeting noticeSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
144 · Notice of proposed saleMar 6, 2026Other filingsSEC
4 · Change in ownershipMar 6, 2026Insider tradeSEC
8-K · Current reportMar 4, 2026Current reportSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
144 · Notice of proposed saleMar 2, 2026Other filingsSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
8-K · Current reportFeb 26, 2026Current reportSEC
424B5 · ProspectusFeb 26, 2026Offer documentSEC
FWP · Free writing prospectusFeb 26, 2026Offer documentSEC
144 · Notice of proposed saleFeb 25, 2026Other filingsSEC
FWP · Free writing prospectusFeb 24, 2026Offer documentSEC
424B5 · ProspectusFeb 24, 2026Offer documentSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
10-K · Annual reportFeb 20, 2026Annual reportSEC
8-K · Current reportFeb 4, 2026ResultsSEC
8-K · Current reportJan 7, 2026ResultsSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
10-Q · Quarterly reportNov 4, 2025Quarterly reportSEC
8-K · Current reportOct 31, 2025ResultsSEC
8-K · Current reportOct 3, 2025ResultsSEC
4 · Change in ownershipOct 2, 2025Insider tradeSEC
4 · Change in ownershipOct 2, 2025Insider tradeSEC
4 · Change in ownershipOct 2, 2025Insider tradeSEC
8-K · Current reportSep 11, 2025Current reportSEC
144 · Notice of proposed saleAug 22, 2025Other filingsSEC
144 · Notice of proposed saleAug 21, 2025Other filingsSEC
4 · Change in ownershipAug 14, 2025Insider tradeSEC
144 · Notice of proposed saleAug 12, 2025Other filingsSEC
144 · Notice of proposed saleAug 8, 2025Other filingsSEC
4 · Change in ownershipAug 7, 2025Insider tradeSEC
144 · Notice of proposed saleAug 5, 2025Other filingsSEC
10-Q · Quarterly reportAug 4, 2025Quarterly reportSEC
8-K · Current reportJul 31, 2025ResultsSEC
3/A · Initial statement of ownership, amendedJul 30, 2025Insider tradeSEC
3 · Initial statement of ownershipJul 11, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 7, 2025Big-stake noticeSEC
8-K · Current reportJul 3, 2025ResultsSEC
4 · Change in ownershipJul 2, 2025Insider tradeSEC
4 · Change in ownershipJul 2, 2025Insider tradeSEC
4 · Change in ownershipJul 2, 2025Insider tradeSEC
11-K · Annual report of an employee planJun 13, 2025Annual reportSEC
SD · Specialized disclosureMay 30, 2025ESG reportSEC
4 · Change in ownershipMay 13, 2025Insider tradeSEC
4 · Change in ownershipMay 13, 2025Insider tradeSEC
4 · Change in ownershipMay 13, 2025Insider tradeSEC
4 · Change in ownershipMay 13, 2025Insider tradeSEC
4 · Change in ownershipMay 13, 2025Insider tradeSEC
4 · Change in ownershipMay 13, 2025Insider tradeSEC
4 · Change in ownershipMay 13, 2025Insider tradeSEC
4 · Change in ownershipMay 13, 2025Insider tradeSEC
4 · Change in ownershipMay 13, 2025Insider tradeSEC
4 · Change in ownershipMay 13, 2025Insider tradeSEC
4 · Change in ownershipMay 13, 2025Insider tradeSEC
4 · Change in ownershipMay 13, 2025Insider tradeSEC
4 · Change in ownershipMay 13, 2025Insider tradeSEC
3 · Initial statement of ownershipMay 13, 2025Insider tradeSEC
8-K · Current reportMay 12, 2025Management or board changeSEC
10-Q · Quarterly reportMay 9, 2025Quarterly reportSEC
8-K · Current reportApr 25, 2025ResultsSEC
8-K · Current reportApr 3, 2025ResultsSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
144 · Notice of proposed saleMar 31, 2025Other filingsSEC
ARS · Annual report to shareholdersMar 24, 2025Annual reportSEC
DEFA14A · Additional proxy materialMar 24, 2025Meeting noticeSEC
DEF 14A · Proxy statementMar 24, 2025Meeting noticeSEC
4 · Change in ownershipMar 18, 2025Insider tradeSEC
144 · Notice of proposed saleMar 14, 2025Other filingsSEC
PRE 14A · Preliminary proxy statementMar 10, 2025Meeting noticeSEC
3 · Initial statement of ownershipMar 10, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
144 · Notice of proposed saleMar 3, 2025Other filingsSEC
144 · Notice of proposed saleMar 3, 2025Other filingsSEC
144 · Notice of proposed saleMar 3, 2025Other filingsSEC
144 · Notice of proposed saleFeb 28, 2025Other filingsSEC
4 · Change in ownershipFeb 28, 2025Insider tradeSEC
4 · Change in ownershipFeb 28, 2025Insider tradeSEC
144 · Notice of proposed saleFeb 28, 2025Other filingsSEC
144 · Notice of proposed saleFeb 26, 2025Other filingsSEC
8-K · Current reportFeb 26, 2025Current reportSEC
144 · Notice of proposed saleFeb 26, 2025Other filingsSEC
4 · Change in ownershipFeb 24, 2025Insider tradeSEC
424B5 · ProspectusFeb 20, 2025Offer documentSEC
144 · Notice of proposed saleFeb 20, 2025Other filingsSEC
8-K · Current reportFeb 19, 2025Current reportSEC
FWP · Free writing prospectusFeb 18, 2025Offer documentSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeFeb 18, 2025Big-stake noticeSEC
424B5 · ProspectusFeb 18, 2025Offer documentSEC
S-3ASR · Registration statementFeb 14, 2025Offer documentSEC
10-K · Annual reportFeb 14, 2025Annual reportSEC
8-K · Current reportFeb 14, 2025Management or board changeSEC
4/A · Change in ownership, amendedFeb 7, 2025Insider tradeSEC
8-K · Current reportFeb 5, 2025Current reportSEC
8-K · Current reportJan 31, 2025ResultsSEC
8-K · Current reportJan 10, 2025Current reportSEC
8-K · Current reportJan 6, 2025ResultsSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipDec 18, 2024Insider tradeSEC
144 · Notice of proposed saleDec 16, 2024Other filingsSEC
8-K · Current reportDec 13, 2024Management or board changeSEC
S-8 · Registration statement for employee plansNov 4, 2024Offer documentSEC
S-8 · Registration statement for employee plansNov 4, 2024Offer documentSEC
10-Q · Quarterly reportNov 4, 2024Quarterly reportSEC
8-K · Current reportOct 30, 2024ResultsSEC

This page holds 200 of 1,010 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from AbbVie Inc.’s releases · as of Oct 26, 2026

Common shares
1,767,616,306
Fully diluted
1,767,616,306

Fully diluted

LineSharesAs of
Common shares1,767,616,306Oct 26, 2026

Share count over time

CountShares
Oct 26, 20261,767,616,306

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Vanguard184M10.4%US$48.2BSep 30, 2026
BlackRock149M8.4%US$39BSep 30, 2026
State Street82.8M4.7%US$21.7BSep 30, 2026
Capital Group68.2M3.9%US$17.8BSep 30, 2026
Geode Capital47.5M2.7%US$12.4BSep 30, 2026
JPMorgan45.3M2.6%US$11.9BSep 30, 2026
Morgan Stanley38.4M2.2%US$10BSep 30, 2026
UBS31.6M1.8%US$8.26BSep 30, 2026
Bank of America26.4M1.5%US$6.9BSep 30, 2026
Fidelity20.3M1.1%US$5.3BSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Franklin Templeton19.8M1.1%US$5.83BSep 30, 2026
Northern Trust19.8M1.1%US$5.17BSep 30, 2026
BNY15M0.85%US$3.93BSep 30, 2026
T. Rowe Price14.8M0.84%US$3.86BSep 30, 2026
Goldman Sachs14.4M0.81%US$3.76BSep 30, 2026
Schwab13M0.74%US$3.41BSep 30, 2026
Amundi11.7M0.66%US$3.07BSep 30, 2026
Legal & General11.5M0.65%US$3.01BSep 30, 2026
Ameriprise11.4M0.64%US$2.98BSep 30, 2026
DWS11.1M0.63%US$2.91BSep 30, 2026
Wellington10.7M0.61%US$2.8BSep 30, 2026
Fisher Asset Management, LLC10.1M0.57%US$2.63BSep 30, 2026
Nuveen9.96M0.56%US$2.6BSep 30, 2026
Raymond James Financial Inc9.91M0.56%US$2.59BSep 30, 2026
Wells Fargo9.08M0.51%US$2.38BSep 30, 2026
RBC7.72M0.44%US$2.02BSep 30, 2026
Invesco6.7M0.38%US$1.75BSep 30, 2026
Dimensional6.64M0.38%US$1.74BSep 30, 2026
MUFG6.13M0.35%US$1.6BSep 30, 2026
Janus Henderson5.99M0.34%US$1.57BSep 30, 2026
State Farm Mutual Automobile Insurance Co5.89M0.33%US$1.54BSep 30, 2026
Swiss National Bank4.83M0.27%US$1.26BSep 30, 2026
Boston Partners4.83M0.27%US$1.26BSep 30, 2026
Envestnet Asset Management Inc4.8M0.27%US$1.25BSep 30, 2026
HSBC4.36M0.25%US$1.14BSep 30, 2026
AllianceBernstein4.34M0.25%US$1.14BSep 30, 2026
Barclays4.26M0.24%US$1.11BSep 30, 2026
TD4.15M0.23%US$1.09BSep 30, 2026
LPL Financial LLC4.14M0.23%US$1.08BSep 30, 2026
National Pension Service4.04M0.23%US$1.06BSep 30, 2026
PNC Financial Services Group, Inc.4.01M0.23%US$1.05BSep 30, 2026
Nordea Investment Management AB3.93M0.22%US$1.04BSep 30, 2026
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main3.85M0.22%US$1.01BSep 30, 2026
Sumitomo Mitsui Trust Group, Inc.3.83M0.22%US$1BSep 30, 2026
BNP Paribas3.79M0.21%US$993MSep 30, 2026
Robeco Institutional Asset Management B.V.3.71M0.21%US$970MSep 30, 2026
Sun Life3.65M0.21%US$961MSep 30, 2026
Corient Private Wealth LP3.6M0.20%US$942MSep 30, 2026
California Public Employees Retirement System3.55M0.20%US$927MSep 30, 2026
Stifel Financial Corp3.54M0.20%US$926MSep 30, 2026

This page holds 50 of 4,243 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund56.1M3.2%US$14.1BJun 30, 2026
Vanguard 500 Index Fund45.8M2.6%US$11.5BJun 30, 2026
iShares Core S&P 500 ETF24.3M1.4%US$6.12BJun 30, 2026
Fidelity 500 Index Fund22.6M1.3%US$4.92BMay 31, 2026
Vanguard Value Index Fund16.8M0.95%US$4.23BJun 30, 2026
State Street(R) Health Care Select Sector SPDR(R) ETF12.5M0.71%US$3.14BJun 30, 2026
American Mutual Fund11.1M0.63%US$2.8BJul 31, 2026
Capital Income Builder10.1M0.57%US$2.52BJul 31, 2026
Vanguard Dividend Appreciation Index Fund10M0.57%US$2.51BJul 31, 2026
Washington Mutual Investors Fund9.63M0.54%US$2.42BJul 31, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Vanguard Institutional Index Fund9.59M0.54%US$2.41BJun 30, 2026
Income Fund of America8.59M0.49%US$2.16BJul 31, 2026
Vanguard High Dividend Yield Index Fund7.13M0.40%US$1.79BJul 31, 2026
Investment Co of America6.53M0.37%US$1.64BJun 30, 2026
Fidelity SAI U.S. Quality Index Fund5.53M0.31%US$1.39BJul 31, 2026
Putnam Large Cap Value Fund5.47M0.31%US$1.37BJul 31, 2026
Vanguard Health Care Index Fund5.31M0.30%US$1.16BMay 31, 2026
iShares Core Dividend Growth ETF5.04M0.29%US$1.27BJul 31, 2026
State Street(R) SPDR(R) Portfolio S&P 500(R) ETF4.21M0.24%US$1.06BJun 30, 2026
Schwab S&P 500 Index Fund3.95M0.22%US$990MJul 31, 2026
American Balanced Fund3.93M0.22%US$989MJun 30, 2026
iShares Core High Dividend ETF3.66M0.21%US$918MJul 31, 2026
iShares Russell 1000 Value ETF3.64M0.21%US$916MJun 30, 2026
Vanguard Health Care Fund3.51M0.20%US$880MJul 31, 2026
Fidelity Total Market Index Fund3.34M0.19%US$728MMay 31, 2026
Columbia Dividend Income Fund3.29M0.19%US$716MMay 31, 2026
JPMorgan Equity Premium Income ETF3.07M0.17%US$771MJun 30, 2026
Growth Fund of America2.97M0.17%US$647MMay 31, 2026
Vanguard Russell 1000 Growth Index Fund2.93M0.17%US$637MMay 31, 2026
MFS Value Fund2.88M0.16%US$626MMay 31, 2026
Fidelity Series Total Market Index Fund2.7M0.15%US$588MMay 31, 2026
JPMorgan Equity Income Fund2.6M0.15%US$653MJun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.2.42M0.14%US$609MJun 30, 2026
iShares Core S&P Total U.S. Stock Market ETF2.28M0.13%US$573MJun 30, 2026
Strategic Advisers U.S. Total Stock Fund2.26M0.13%US$492MMay 31, 2026
Select Biotechnology Portfolio2.23M0.13%US$486MMay 31, 2026
Capital Group Dividend Value ETF2.18M0.12%US$475MMay 31, 2026
JPMorgan U.S. Equity Fund2.16M0.12%US$544MJun 30, 2026
Franklin Rising Dividends Fund2.1M0.12%US$530MJun 30, 2026
College Retirement Equities Fund - Total Global Stock Account2.1M0.12%US$528MJun 30, 2026
Vanguard Large-Cap Index Fund2.06M0.12%US$519MJun 30, 2026
Franklin Income Fund2M0.11%US$503MJun 30, 2026
Schwab U.S. Large-Cap ETF1.88M0.11%US$408MMay 31, 2026
iShares S&P 500 Growth ETF1.72M0.10%US$432MJun 30, 2026
S&P 500 Index Master Portfolio1.62M0.09%US$407MJun 30, 2026
iShares S&P 500 Value ETF1.57M0.09%US$395MJun 30, 2026
Vanguard Total World Stock Index Fund1.5M0.08%US$377MJul 31, 2026
Fidelity Blue Chip Growth Fund1.5M0.08%US$376MJul 31, 2026
Capital World Growth & Income Fund1.47M0.08%US$321MMay 31, 2026
Nuveen Equity Index Fund1.47M0.08%US$369MJul 31, 2026

This page holds 50 of 1,405 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Stewart Jeffrey Ryan
Officer: EVP, CHIEF COMMERCIAL OFFICER
Sale40,619USD 293.60US$11.9MNov 9, 2026
Donoghoe Nicholas
Officer: EVP, CHIEF BUS/STRAT OFFICER
Sale32,710USD 250.00US$8.18MAug 14, 2026

Big stakes

StakeStakeSharesDateFiling
Vanguard Capital Management LLC7.51%133MMar 31, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Glenn F Tilton
Other companies: Phillips 66 (Director · Since at least May 1, 2012); Corning Incorporated (Director · Nov 30, 2010 – Feb 1, 2012 · Past); Abbott Laboratories (Director · Apr 27, 2007 – Apr 29, 2022 · Past); United Airlines Holdings, Inc. (Director · Feb 1, 2006 – Jun 12, 2013 · Past); Txu Corp (Director · Jan 9, 2006 – Jan 9, 2007 · Past); Lincoln National Corporation (Director · Dec 30, 2005 – Mar 31, 2007 · Past)
Director · Dec 12, 2012 – May 9, 2025 · Past
Henry Gosebruch
Other companies: ANI Pharmaceuticals, Inc. (Director · Since at least Aug 19, 2026); Neumora Therapeutics, Inc. (President & CEO, Director · Sep 14, 2023 – Feb 14, 2024 · Past); Acelyrin, Inc. (Director · May 4, 2023 – May 21, 2025 · Past); Aptinyx Inc (Director · May 6, 2019 – May 26, 2022 · Past)
EVP, Chief Strategy Officer · Oct 30, 2017 – May 16, 2022 · Past
Carlos Albán
Other companies: Solventum Corporation (Director · Since at least Apr 1, 2024); SpringWorks Therapeutics Inc (Director · Since at least Jul 14, 2022); Abbott Laboratories (Senior Vice President · Oct 15, 2009 – Dec 1, 2012 · Past)
Vice Chairman · Dec 7, 2012 – Nov 16, 2020 · Past
Michael Severino
Other companies: Sarepta Therapeutics, Inc. (Chief Executive Officer · Since at least Jul 27, 2026); Viatris Inc. (Director · Since at least May 5, 2025); Avantor, Inc. (Director · Since at least Apr 22, 2020)
Vice Chairman · Jun 2, 2014 – May 23, 2022 · Past
Thomas C. Freyman
Other companies: Hanger Inc (Director · Nov 14, 2017 – Oct 3, 2022 · Past); Abbott Laboratories (Executive Vice President · Feb 19, 2016 – Jul 29, 2016 · Past); Tenneco Inc (Director · Jul 14, 2015 – Nov 17, 2022 · Past)
Director · Since at least May 8, 2020
Robert J Alpern
Other companies: Abbott Laboratories (Director · Since at least Oct 10, 2008); Tricida Inc (Director · Jun 27, 2018 – Nov 23, 2022 · Past)
Director · Since at least Dec 12, 2012
Roxanne Austin
Other companies: CrowdStrike Holdings, Inc. (President, Austin Investment Advisors · Since at least Jun 17, 2026); Freshworks Inc. (Director · Since at least Apr 1, 2026)
Director · Since at least May 8, 2026
Roy S Roberts
Other companies: Abbott Laboratories (Director · Dec 31, 2005 – Jan 31, 2011 · Past); Burlington Northern Santa Fe Corp (Director · Dec 30, 2005 – Feb 12, 2010 · Past)
Director · Dec 12, 2012 – May 8, 2015 · Past
Thomas J. Falk
Other companies: Lockheed Martin Corporation (Director · Since at least Jan 30, 2020); Kimberly-Clark Corporation (Executive Chairman, Director · Apr 23, 2019 – Dec 11, 2019 · Past)
Director · Since at least May 9, 2025
William J Chase
Other companies: GRAIL, Inc. (Director · Since at least Jun 11, 2024); Intellia Therapeutics, Inc. (Director · Since at least Apr 14, 2023)
EVP, Finance & Administration · Dec 7, 2012 – Jun 26, 2019 · Past
All 32 people
PersonSeat
Azita Saleki-Gerhardt
Other companies: Entegris, Inc. (Director · Since at least May 1, 2019)
EVP, CHIEF OPERATIONS OFFICER · Since at least Feb 20, 2020
Brett J. Hart
Other companies: United Airlines Holdings, Inc. (President · Since at least Apr 26, 2016)
President · Since at least May 6, 2016
Edward J. Rapp
Other companies: Xos, Inc. (Director · Since at least Aug 20, 2021)
Director · Since at least Mar 31, 2019
Elaine Sorg
Other companies: Artiva Biotherapeutics, Inc. (Director · Since at least Feb 18, 2026)
SVP, US COMMERCIAL OPERATIONS · Nov 9, 2020 – Apr 25, 2023 · Past
Frederick H. Waddell
Other companies: International Business Machines Corporation (Director · Since at least Sep 29, 2023)
Director · Since at least May 3, 2024
Jennifer L Davis
Other companies: Procter & Gamble Company (the) (CEO - Health Care · Since at least Apr 1, 2022)
Director · Since at least Oct 11, 2023
Richard A Gonzalez
Other companies: Abbott Laboratories (Executive Vice President · Nov 17, 2005 – Apr 6, 2012 · Past)
Director · Dec 7, 2012 – Mar 31, 2025 · Past
Adelle InfanteCorporate Communications · Since at least Sep 2, 2026
Brian L DurkinVP, CONTROLLER · Oct 16, 2018 – Feb 28, 2023 · Past
Carrie C StromSVP & PRES GLOBAL ALLERG AESTH · May 8, 2020 – May 11, 2023 · Past
David Ryan PurdueSVP, Controller · Since at least Mar 1, 2025
Demetris D CrumEVP, CHIEF HR OFFICER · Since at least Jul 1, 2025
Jeffrey Ryan StewartEVP, CHIEF COMMERCIAL OFFICER · Since at least Nov 9, 2026
Kevin K BuckbeeSVP, CONTROLLER · Mar 1, 2023 – Feb 28, 2025 · Past
Melody B. MeyerDirector · Since at least May 9, 2025
Perry C SiatisEVP, GC AND SECRETARY · Since at least Oct 17, 2022
Rebecca B. RobertsDirector · Since at least May 8, 2026
Robert A. MichaelChairman of the Board and Chief Executive Officer · Since at least Oct 30, 2026
Susan E QuagginDirector · Since at least Oct 11, 2023
Thomas J HudsonSVP, CSO, GLOBAL RESEARCH · Feb 18, 2021 – Feb 28, 2024 · Past
Timothy J RichmondEVP, CHIEF HR OFFICER · Dec 7, 2012 – Feb 28, 2025 · Past
William H.L. BurnsideDirector · Since at least May 6, 2016

Open People

Log in to ask 6ix AI your own questions about AbbVie Inc.